FindTrial
Sign In

Phase 2 study of RK-023 patients with androgenetic alopecia (male pattern baldness) -A study for safety and preliminary estimation of hair re-growth in male subjects with androgenetic alopecia treated for 13 weeks with RK-023-

Phase 2 study of RK-023 patients with androgenetic alopecia (male pattern baldness) -A study for safety and preliminary estimation of hair re-growth in male subjects with androgenetic alopecia treated for 13 weeks with RK-023-

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220997
Enrollment
48
Registered
2010-02-08
Start date
2010-02-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia (male pattern baldness)

Interventions

investigational material(s) Generic name etc : RK-023 INN of investigational material : Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investigational materi

Sponsors

R-Tech Ueno, Ltd
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Men aged between 20 and 44 years with an androgenetic alopecia rated as Takashima modified classification of Norwood-Hamiltonstage, IIv, IIIv and IV

Exclusion criteria

Exclusion criteria: Subjects with the complication that treatment is required

Design outcomes

Primary

MeasureTime frame
Number of cases with side-effects (Safety), change for anagen hair ratio (Efficacy) Clinical valuation (Safety) Phototrichogram (Efficacy)—

Secondary

MeasureTime frame
Global photograph of vertex (Efficacy) Global photograph of vertex—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026